In order to develop improved binding antagonists from the polo-like kinase 1 (Plk1) polo-box domain (PBD), we optimized interactions from the known high affinity 5-mer peptide, PLHSpT using oxime-based post-solid-phase peptide diversification from the (((((( em 4S /em ) epimer (8) (Assisting Information Figure S8). abrogates binding.4 We observed that S/A variations, 7(S4A) and 8(S4A),… Continue reading In order to develop improved binding antagonists from the polo-like kinase